...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019

November 16 is a Saturday. If topline is positive it could make for an even more ‘interesting’ market opening on Monday, November 18 should the numbers support a strong trial result. Ideally I suppose that would be a RRR% that blows the doors off the CV death component (is that like a 1 pt. MACE?) and improvement in eGFR and MoCA numbers in whatever way that is significant. It’s all a lot to ask for, but that’s why we’re all here biting our nails. :)

Share
New Message
Please login to post a reply